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Background: There is a need to standardise non-invasive measurements of liver iron concentrations (LIC) so clear
inferences can be drawn about body iron levels that are associated with hepatic and extra-hepatic complications
of iron overload. Since the first demonstration of an inverse relationship between biopsy LIC and liver magnetic
resonance (MR) using a proof-of-concept T2* sequence, MR technology has advanced dramatically with a shorter
minimum echo-time, closer inter-echo spacing and constant repetition time. These important advances allow more
accurate calculation of liver T2* especially in patients with high LIC.
Methods: Here, we used an optimised liver T2* sequence calibrated against 50 liver biopsy samples on 25 patients with
transfusional haemosiderosis using ordinary least squares linear regression, and assessed the method reproducibility in 96
scans over an LIC range up to 42 mg/g dry weight (dw) using Bland-Altman plots. Using mixed model linear regression
we compared the new T2*-LIC with R2-LIC (Ferriscan) on 92 scans in 54 patients with transfusional haemosiderosis and
examined method agreement using Bland-Altman approach.
Results: Strong linear correlation between ln(T2*) and ln(LIC) led to the calibration equation LIC = 31.94(T2*)-1.014. This
yielded LIC values approximately 2.2 times higher than the proof-of-concept T2* method. Comparing this new T2*-LIC
with the R2-LIC (Ferriscan) technique in 92 scans, we observed a close relationship between the two methods for values
up to 10 mg/g dw, however the method agreement was poor.
Conclusions: New calibration of T2* against liver biopsy estimates LIC in a reproducible way, correcting the proof-of-
concept calibration by 2.2 times. Due to poor agreement, both methods should be used separately to diagnose or rule
out liver iron overload in patients with increased ferritin.
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The measurement of liver iron concentration (LIC) is
clinically useful because LIC reflects total body iron in a
predictable way [1]. Changes in LIC over time also
reflect total iron balance and hence the efficiency and
effectiveness of chelation therapy in controlling total
body iron levels [2,3]. Non-invasive estimation of LIC is
increasingly used to follow responses to chelation
therapy [4]. This is because of the limitations of serum* Correspondence: maciej.garbowski@ucl.ac.uk
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article, unless otherwise stated.ferritin as a single measure of iron overload and response
to chelation treatment, and also because variability in LIC
accounts for only 57% of variability in serum ferritin [5].
Serum ferritin may be disproportionately increased
relative to LIC by hepatitis and liver damage, generalised
inflammation, and by vaso-occlusive syndromes in sickle
cell disorders [6]. Conversely, serum ferritin is dispropor-
tionately decreased relative to LIC in ascorbate deficiency
[7] and in conditions where iron preferentially loads
hepatocytes rather than macrophages, such as thalassemia
intermedia [8]. Furthermore, the relationship of serum
ferritin to LIC, and their trajectories [9], may differ in
different chelation regimes [10]. Thus, in the moderntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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important tool. Its clinical applicability increases when
it can be performed non-invasively with standardised
methodology that is comparable across treatment centres
worldwide.
A variety of non-invasive methods have been used to
measure LIC including liver susceptometry (SQUID),
[11,12], T2-weighted spin-echo MR with [13] or without
signal intensity ratios (SIR) to adjacent tissues, [14] and
T2* gradient-echo MR with [15] or without SIR, [16-18].
It is important to understand how values derived with
these various approaches relate to each other, so that
responses to chelation therapy in different studies can be
compared and thresholds for treatment intensification can
be meaningfully identified.
The T2* MR sequence was developed to measure
myocardial iron, but in the first description and initial
validation of the use of myocardial T2*, the relation
between liver T2* and LIC (measured by biopsy) was
documented [16]. The inclusion of the liver analysis at
that time was intended to demonstrate a relation between
tissue iron concentration and T2*, as myocardial biopsy
was impractical and deemed unreliable. At that stage, T2*
was not intended or suitable to be used as a standardised
method for LIC measurement. Indeed, the curve relating
T2* to LIC was known not to reflect a true calibration,
because a number of technical issues in the T2* acquisition
made it unsuitable for liver iron measurement, the most
important factor being that the first echo time (TE) was
too long for LIC measurement. An additional factor
limiting this first proof-of-concept T2* sequence was
that the repetition time (TR) was not constant, which
introduced a known error due to the T1 shortening
effect of iron. More recently, other MR methods have been
introduced specifically for LIC determination, [14,15] of
which the R2 Ferriscan technique [14] is currently the
most widely used. However, if the T2* method were
robustly calibrated for LIC determination, it would be
convenient to measure liver and heart iron at the
same time using the rapid T2* technique.
Since the initial T2* method was described [16], there
have been major improvements in scanner technology and
hardware. In the original paper [16], the shortest available
TE was 2.2 ms, and 7 further images were acquired with TE
ranging up to 20.1 ms, each of which required a separate
breath-hold. Using a modern T2* sequence, the shortest TE
is typically <1 ms, the TR is held constant for all TE’s, and
all images can be acquired in a single breath-hold.
This makes the calculation of liver T2* considerably more
accurate, especially at higher liver iron concentrations
where T2* is very short, eliminates the T1 error, and
eliminates mis-registration error between breath-holds.
We now report the calibration of liver T2* MR using a
state-of-the-art sequence against LIC obtained fromparaffin embedded liver biopsies [4,19]. We also report
the relation between T2*-LIC values and LIC values
obtained by R2 Ferriscan (R2-LIC).
Methods
Patients
For the calibration analysis we retrospectively studied
25 patients with transfusional hemosiderosis, including
20 Thalassemia Major, 2 Diamond-Blackfan Anemia,
2 Congenital Sideroblastic Anemia, 1 Pyruvate Kinase
Deficiency Anemia, in whom 50 liver biopsies were
undertaken at UCLH as part of clinical iron chelation
studies on deferasirox; [2,4] patients were also being
monitored with annual liver and heart MR scans ac-
cording to standard clinical management (calibration
cohort).
For comparison of T2*-LIC with R2-LIC, 92 scans were
performed in 54 patients enrolled in the deferasirox EPIC
study [20] and monitored according to standard clinical
management with annual liver and heart MR scans
(comparison cohort). All patients had transfusional
hemosiderosis treated with deferasirox (36 Thalassemia
Major, 7 Sickle Cell Anemia, 4 Myelodysplastic Syndrome,
3 Diamond-Blackfan Anemia, 2 Red Cell Aplasia, 2 Pyruvate
Kinase Deficiency Anemia).
31 healthy volunteers were invited to participate in the
study. IRB approval was granted to the study and all
patients and healthy volunteers signed informed con-
sent forms before undergoing scans or liver biopsy.
The study was approved by the Royal Brompton and
Harefield Research Ethics Committee.
Liver biopsy
Biopsy LIC was measured in a single central laboratory
in Rennes, France (Clinique des Maladies du Foie [Clinic
for Hepatic Illnesses], Centre Hospitalier Universitaire)
on paraffin embedded sections as previously described
[21,22]. Briefly, after obtaining each patient’s consent, a
16G thru-cut needle was passed into the right lobe of
the liver under local anaesthesia and aseptic conditions;
liver tissue was placed immediately in formaldehyde
solution, routinely processed and embedded into wax
by local pathology laboratory, batched and sent to Rennes
for analysis.
MR studies
All MR scans were performed on a 1.5 T Sonata MR
scanner (Siemens, Germany) using a 4-channel anterior
phased array coil at Royal Brompton Hospital, London
(RBH). A transverse slice through the centre of the liver
was imaged using a multi-echo single breath-hold
gradient echo T2* sequence with a range of echo times
(TE 0.93-16.0 ms). T2* was measured using Thalassemia
Tools (Cardiovascular Imaging Solutions, London, UK)
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liver tissue, avoiding blood vessels and other sources
of artefact. To correct for background noise, a truncation
method was used for curve fitting [23] (Figure 1A-B).
All T2* measurements were performed in triplicate by
two independent observers choosing three separate
ROIs to analyse. The ROIs were chosen to be as large
as possible in three separate areas of the liver (anterior,
mid/lateral and posterior). The observers were blinded
to each other’s and to liver biopsy results. T2* is con-
ventionally expressed in milliseconds [ms], while the
units of its reciprocal R2* are s−1 with R2*[s−1] =1000/
(T2*[ms]). Liver R2* in healthy volunteers (n = 31) was
37.0 ± 1.1 s−1 (mean ± SEM), SD 6.1 s−1, range 28.7 to
54.4 s−1.
R2-LIC (Ferriscan) sequences were obtained on the
same scanner according to the EPIC study protocol, as
reviewed recently [24].-1
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purposes however treated separately to estimate inter-
observer reproducibility. For inter-observer liver R2*
agreement, 96 liver R2* scans from 38 patients were in-
dependently evaluated in triplicate by two observers as
described above (Figure 1) and analysed using Bland-
Altman plots [25]. The degree of relationship between
log-transformed biopsy LIC and liver R2* or T2* was es-
timated by Pearson correlation method. Mixed model
linear regression was used with patients declared as ran-
dom effects and predictor variables as fixed effects.
Where the effect of nesting of the data within patients
was insignificant (by a likelihood ratio test), ordinary
least squares regression (LSR) was used to fit the model
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graphpad.com, and STATA Ver 10.1 (Stata Corp, College
Station, TX).
Results
Reproducibility and predictability of R2*
On difference-versus-mean Bland-Altman analysis
(Figure 1), there was good inter-observer agreement,
with increasing deviation from zero for R2* > 500 s−1.
Bias was negligible at 0.61%, 95% limits of agreement
(LoA) were approximately 8 and 9% below and above
the bias, corresponding to about 1.5 mg Fe/g dw in
each direction (see Equation 1). This was considered
clinically acceptable, especially for mean liver R2*
values <400 s−1 where the inter-observer agreement
was robust with the spread nearly limited to the 95% CI of
the bias only.
Relationship of T2* to LIC
In total, 50 data pairs (biopsy LIC value and corresponding
liver T2*) were available for analysis on 25 patients.
Median biopsy-to-scan window was 78 days (IQR 39–160,
range 2–228). LIC values ranged from 1.7 to 42.3 mg/g dw
(median 12.6). Nesting effect of patients was insignificant
and did not warrant a mixed model regression approach.
T2* and LIC showed curvilinear relationship (Figure 2A),
however assumptions of distribution and variance of re-
siduals were not met on LSR. Therefore further analysis
was performed after log-transformation of both variables
(Figure 2C) which were highly correlated with Pearson
r = −0.94. Linear LSR lnLIC = 3.464-1.014ln(T2*) was expo-
nentiated to a non-linear model LIC = 31.94(T2 *)− 1.014
(Equation 1) with r-squared = 0.89, which for 5 ms corre-
sponds to 6.24 mg/g dw (95% CI 5.67 to 6.88 or 91-110%)
and for 2 ms to 15.82 mg/g dw (14.46 to 17.31 or 91-109%).
Therefore the early T2* method [16] estimating LIC
at 6.86 mg/g dw for T2* of 2 ms should be corrected
by an average factor of × 2.2 + 0.57 to obtain values
comparable with present calibration.
Relationship of R2* to LIC
With T2* values expressed as R2* (=1000/T2*), the
relationship initially looked linear, however non-normally
distributed residuals and heteroscedasticity (fanning-out
effect) prevented both linear and non-linear LSR analysis
(Figure 2B). Log-log transformed data allowed for a linear
LSR model (Figure 2D), which for an R2* of 200 s−1 gave
the same best fit and 95% confidence interval (CI)
LIC value as its T2* equivalent of 5 ms in the T2* model.
Because parameter estimation by unconstrained regres-
sion showed larger standard error of the intercept than in
the T2* model, further analysis was performed using the
calibration Equation 1. Due to the nature of the reciprocal
relation between T2* and R2*, a greater intercept error isintroduced when R2* is derived from T2* and compared
to liver iron. For this reason, we have chosen to use T2*
for our calibration.
LIC did not relate to biopsy grading (p = 0.15, one-way
ANOVA), but showed a weak significant relationship
between LIC and staging of fibrosis (p < 0.01, one-way
ANOVA with post-test for linear trend relating stage (1–5)
to mean LIC: slope 1.99, r-squared 0.18, p < 0.001). In view
of the latter, we examined whether exclusion of stage 4 and
5 data pairs altered the calibration equation, however
differences in absolute sum of squares for both models
were insignificant (p > 0.82) therefore no changes to
Equation 1 were made (data not shown).
We have also examined whether excluding data pairs
with large biopsy-MR window alters the LIC to T2*
relationship, and have therefore compared a linear
model based data with a median window of 28 days
(IQR 14–45, range 2–56, n = 17) with Equation 1,
however there was no significant difference between
absolute sum of squares (p = 0.06, data not shown).
Relationship of new T2* (R2*) calibration to R2 (Ferriscan)
LIC measurements
The LIC values obtained with the above recalibrated T2*
method were compared with LIC values obtained using
the R2 (Ferriscan) method in 92 scans performed in 54
patients. The median time window between the T2* and
R2 scan was 13 days (range 0 to 91). R2-LIC values were
measured across the entire clinically relevant range from
1.0 to 43.3 mg/g dw (median 11.95, IQR 5.50 to 21.45).
T2*-LIC values ranged from 1.25 to 41.10 mg/g dw
(median 12.20, IQR 4.65 to 19.75). Data pairs were also
restricted to those obtained within 30 days and the two
data sets compared (not shown), however there was no
significant difference in the regression line or the data
scatter between the two sets.
Figure 3 shows the relation between R2-LIC (Ferriscan)
and T2*-LIC derived from Equation 1. With heteroscedastic
data scatter (Figure 3A), the whole range relationship
could not be described by linear LSR unless the data
were log-transformed. Mixed model regression of the
log-transformed data (significant patient nesting effect
p < 0.001) showed ln(R2-LIC) = 1.04 × ln(T2*-LIC)-0.08,
exponentiated to (R2-LIC) = 0.93 × (T2*-LIC)1.04. The
best-fit line closely follows the line of identity (95% CI of
both constants includes 1), however confident predic-
tion of higher values is impossible due to increasing
scatter, which is supported by low explained variance
(r-squared = 0.65) and lack of agreement in the whole
range Bland-Altman plot (Figure 3B). Low range data
however, shows that the scatter is relatively limited
(Figure 3A red). Consequently, better agreement between
the two methods is obtained at LIC < 10 mg/g dw
(here further analysed in 37 scans on 26 patients), with a
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Figure 2 The calibration of T2* and R2* models for LIC estimation. (A) The relationship of liver T2* to LIC obtained by biopsy in 50 samples.
The regression fit from Figure 2C was plotted onto the data after exponentiation: LIC = 31.94(T2*)-1.014 with 95% CI 27.8 to 36.7 (87-115%) for the
first term and −1.118 to −0.91 (110-90%) for the exponent. (B) The relationship of liver R2* (=1000/T2*) to LIC of the data in 2A, with regression
line from the model in 2D after exponentiation: LIC = 0.029R2*1.014; 95% CI 0.016 to 0.054 (55-186%) for the first constant, 0.910 to 1.118 (90-110%) for
the exponent. (C) Log-log plot of LIC versus liver T2*: Pearson r = −0.94 (95% CI −0.97 to 0.91, p < 0.0001); linear regression: ln(LIC) = 3.464-1.014ln(T2*);
slope SE = 0.052, 95% CI −1.118 to −0.9 (110-90%); intercept SE = 0.069, 95% CI 3.325 to 3.603 (96-104%), r squared 0.89. (D) Log-log plot of LIC versus
liver R2*: Pearson r = 0.94 (95% CI 0.90 to 0.97, p < 0.0001); linear regression: ln(LIC) = 1.014ln(R2*)-3.54; slope SE = 0.052, 95% CI 0.910 to 1.118
(90-110%); intercept SE = 0.30, 95% CI −4.152 to −2.928 (117-83%); r squared 0.89.
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dw (not shown). This however corresponds to ±45% on
percentage difference Bland-Altman plots after linear cor-
rection for non-uniform scatter (Figure 3D). For the data-
points defined by R2-LIC <10 mg/g dw (see Figure 3A red
circle), there does appear to be a much clearer, linear rela-
tionship using the values on their original (untransformed)
scales. The regression diagnostic plots (not shown) andcomparison of the original and logged data graphs
(Figure 3A, C), suggest the prediction intervals for the ori-
ginal data to be a better fit. Mixed model linear regression
on the limited range data (nesting effect p = 0.012)
gives (R2-LIC) = 0.87 × (T2*-LIC) + 0.55 (equation 2)
with r-squared = 0.86. Insignificant intercept (p = 0.09,
95% CI −0.09 to 1.19) allows forcing the model
through zero, which leads to a proportionality slope
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Figure 3 Relationship of new T2*-LIC to R2-LIC (Ferriscan) measurements. (A) R2-LIC plotted against T2*-LIC (derived from Equation 1) for
comparison cohort; range with lowest scatter circled. Mixed model regression on whole range log-transformed data ln(R2-LIC) = 1.04×ln(T2*-LIC)-
0.08, with slope and intercept 95% CI of 0.96 to 1.11 (p < 0.001) and −0.26 to 0.11 (p = ns), is shown here exponentiated to R2-LIC = 0.83×T2*-
LIC1.04 with 95% CI 0.96 to 1.11 and 0.55 to 1.29, r squared = 0.65. (B) Whole range Bland-Altman plot of percentage difference vs mean LIC with
non-uniform scatter with linear regression correction. Corrected bias is −1.29*(mean LIC)+23.03; absolute residuals R were related to LIC: R = 0.47*
(mean LIC)+17.44, p = 0.01, therefore, accounting for growth in variance, 95% LoA were from −0.14*(mean LIC)+65.9 to −2.44*(mean LIC)-19.8 or
changing from ±45 to ±90% across the whole range. (C) Mixed model linear regression of R2-LIC on T2*-LIC for R2-LIC range 0–10 mg/g dw: R2-
LIC = 0.87 × R2*LIC-0.55, slope 95% CI 0.74 to 0.99 (p < 0.001), intercept −0.01 to 1.19 (p = 0.089); r squared = 0.86. Insignificant intercept can be
abandoned to give a proportionality with a slope of 0.96, 95% CI 0.89-1.02, p < 0.001, which being indistinguishable from 1, follows the line of
identity. (D) Bland-Altman plot of the mean of the two methods (x-axis) plotted against their percentage difference (y-axis) for the range marked
by circle in 3A, which for R2-LIC values <10 mg/g dw (here in 37 scans on 26 patients) shows non-uniform scatter corrected by linear regression.
Corrected bias is −4.51*(mean LIC)+40.23, p = 0.007, SD of residuals 23.22%. Absolute residuals did not relate to LIC (p = 0.99), therefore 95%LoA
were bias ± 1.96*23.22% or ±45.51%.
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with no significant change to r-squared (0.84), or of 0.03
for liver R2* only (<400 s−1). Given that the slope is
indistinguishable from 1, this essentially shows an
identity relationship between the two methods within
the limited range. However percentage difference
Bland-Altman plot for this range still shows poor agree-
ment even after linear correction for non-uniform scatter
(±45%, Figure 3D).The inter-observer repeatability coefficient (IRC) for
T2*-LIC was 0.37 mg/g dw over this range (0-10 mg/g
dw), as calculated from within-subject variance (one-way
ANOVA with patient as group) [25]. IRC can be compared
with the interval between 95% LoA on difference
Bland-Altman plot of the two methods (not shown)
such that ±0.37 i.e. 0.74 versus 3.87 (from −1.31 to
2.56 mg/g dw) would account for approximately 19% of
the variability represented by the range between 95% LoA.
Garbowski et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:40 Page 7 of 11
http://jcmr-online.com/content/16/1/40Discussion
Non-invasive assessment of LIC is increasingly used as
an alternative to biopsy and in order for clinicians to
have evidence-based guidelines for the management of
iron overload, it is important that LIC measurements are
comparable across studies, treatment centres and conti-
nents. Recently, considerable effort has been undertaken to
standardise the assessment of myocardial iron with T2*
across centres internationally [23,26], but knowledge about
how different measures of LIC compare is relatively limited.
It is convenient for patients and clinicians if LIC can be
assessed by MRI at the same time as myocardial T2*
estimation, and this is possible in principle using T2*
methodology. However the measurement of LIC by
T2*, as originally described in 2001, [16] was undertaken
as a proof of concept: namely that tissue T2* was related
to tissue iron concentrations. This was an early MR tech-
nique, and not in any way optimised for the liver, where
high iron concentrations cause low T2* values requiring
very short minimum echo-times for accurate measure-
ment. Such short echo times were not achievable with
typical MR technology in 2001. However, since that time,
it has become clear that a calibration of liver T2* is
required which uses current improved MRI methodology
and which allows comparisons with other available
techniques.
A less widely appreciated reason for why further
calibration is necessary is that biopsy LIC, the so-called
‘gold standard’ for LIC determination, is also not standar-
dised and highly variable. The variability of needle biopsy
LIC is dependent on the biopsy specimen size [27] (CV of
approximately 19% when <4 mg/g dw [28] and 9% when
>9 mg/g dw [29]), on fibrosis content, [27] and the pres-
ence of cirrhosis (CV >40%) [28,30]. Biopsy LIC determin-
ation also varies considerably between laboratories due to
differences in the real or perceived ratios of wet-to-dry
weights of tissue samples; e.g. the mean wet-to-dry weight
ratio for vacuum-dried fresh tissue was 3.76, but up to
6.26 in paraffin-embedded de-waxed tissue, [22] resulting
in a corresponding difference in the measured dry tissue
iron concentration. In the original T2* publication by
Anderson, [16] biochemical determination of LIC was
performed on formalin fixed cores but not on paraffin
embedded tissue, [29] which could explain in part
why there is an approximately 2-fold difference with
the calibration in this paper where paraffin embedded
biopsies were used. Such differences have also been
an issue with SQUID; in a recent large-scale study an
approximately two-fold correction factor was required
between biopsy and SQUID methodology [2,4].
Interestingly, the calibration of T2* in this paper, gives
values close to those obtained with the R2 technique,
however agreement between both methods remains poor
over the whole range of measurements. As scatter wasnon-uniform, showing lower stable variance and the pro-
portionality slope indistinguishable from 1 in the low
range of measurements (Figure 3D), we wished to exam-
ine whether method agreement improves if comparison is
limited to that range. However limits of agreement in this
range are still unacceptable at ±45%.
Because the calibrations in this paper were retrospective,
utilising MRI data obtained during routine testing, and
biopsy samples obtained as part of chelator studies, [2,4]
the timing of biopsies relative to MRI scans was not
necessarily coordinated so that the biopsy-to-scan intervals
were variable. However, no significant difference was found
between a model based on narrow biopsy-to-scan
windows and that described by Equation 1. The most
likely explanation of this finding is that, as chelation-
induced difference in LIC over time increases with
biopsy-to-scan window and may therefore cause T2*
to overestimate or underestimate LIC (by preceding or
following biopsy, respectively), the positive and negative
time windows distribute randomly around zero, and
their estimation bias is effectively cancelled out (data
not shown). Otherwise one would have to postulate
long-term stability of LIC, which is likely not to be
the case.
We have attempted to examine the reproducibility of
the current T2* (R2*) methodology at a single centre
(RBH). This has been achieved with two independent
observers, each choosing the ROI to examine in triplicate,
and by then comparing the intra-observer mean liver R2*
between the two observers (inter-observer reproducibility,
IOR). This IOR is acceptable over a wide range of R2*,
being particularly good for R2* < 500 s−1 or LIC ≈ 15 mg/g
dw (see Figure 1C-D). Other reproducibility estimates
were beyond the scope of this study, as it relied on the
analysis of data generated either as a part of routine
monitoring of patients, or from scans obtained during
the assessment of new chelation therapies [2,4,24]. Such
studies would be of value if this liver T2* technique was to
be used in those international centres where myocardial
T2* has already been validated [23,26].
IRC-derived variability of T2*-LIC constitutes 19% of
the variability between R2-LIC and T2*-LIC represented
by the 95% LoA interval (Figure 3D). Other sources of
variability related to repeatability and reproducibility are
unlikely to explain the poor agreement between both
methods as reproducibility studies for T2* [26,31,32]
and R2 LIC indicate (excellent single centre inter-scan
[14], although not multi-centre with broad LoA −71 to
74% [33]). Choice of ROI is also not likely to reduce
agreement as inrer-slice reproducibility is high [14,17] and
the magnitude of significant increase in LIC variability from
small-ROI vs whole-liver methods although significant is
practically too small [34] to explain the poor agreement
we and others have observed. Non-repeatability-related
Table 1 Comparison of LIC calibration methods
Authors Method Liver slice
thickness
ROI size ROI number Localization
within liver
TE, step [ms] TR [ms] Breath-hold Background noise
reduction
Notes
St Pierre et al. [14] T2 5 mm, 5 mm
gap
Whole liver 1 Largest axial slice 6-18, 3 2500 Single Voxel intensity
smoothing
SSE
Wood et al. [17] T2* 15 mm Whole liver 1 Mid-hepatic slice 0.8-4.8, 0.25 25 Single Variable offset Single echo gradient echo
Wood et al. [17] T2 15 mm, 5 mm
gap
Whole liver 4 Entire liver boundary
without obvious hilar
vessels
3.5-30, nd nd Single Variable offset Single echo 120°-120°
Hahn echo
Hankins et al. [18] T2* 10 mm Small, variable 1 Transverse slice, at the
level of main portal vein
origin, excluding vessels
and bile ducts
1.1-17.3, 0.8 nd One per TE Truncation Multiecho gradient echo
McCarville et al. [34] T2* 10 mm Whole liver 1 Transverse, at the level
of main portal vein origin
1.1-17.3, 0.8 200 Single nd Multiecho gradient echo
McCarville et al. [34] T2* 10 mm Small, variable 1 Right lobe, excluding
vessels and bile ducts
1.1-17.3, 0.8 200 Single nd Multiecho gradient echo
Gandon et al. [15] T2* 10 mm Small, variable 3 Right lobe 4-21, nd 120 nd Saturation threshold
defined
GRE
Garbowski et al. T2* 10 mm Small, variable 3 Transverse mid-hepatic
slice right lobe, excluding
vessels and bile ducts
0.93-16, nd nd Single Truncation Multiecho gradient echo
All scanners are 1.5 T; TE, echo time; TR, repetition time; SSE, single echo spin echo; GRE, gradient recalled echo; ROI, region of interest; nd, no data.
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different sensitivity to noise of both methods, to iron
particle size, clumping, distribution and resultant proton
mobility [35] within tissue is perhaps a more likely reason
for lack of within-patient agreement. Wood and colleagues
have recently shown that, when viewed separately, both
methods adequately reflect absolute levels and trends in
LIC in patients with iron overload on chelation ther-
apy [36,37], but the fact that they cannot be used
interchangeably due to poor cross-sectional agreement
(±50%), despite excellent concordance of chelation
efficiency estimates derived from them, all point to a
possibility that methods access slightly different pools
of iron (e.g. hepatocyte vs macrophage, haemosiderin
at different stages of maturation) which nonetheless
change in parallel during chelation or that they sample
them in a different way. Differences in acquisition methods
may also affect agreement (see Table 1). The R2 Ferriscan
method uses a spin echo sequence, [14] unlike the gradient
echo sequences used for T2* in this paper. This decreases
the effect of surrounding tissue on the signal but also has a
non-linear relationship to LIC particularly at high LIC
values. In the MRI technique described by Gandon, [15]
which used a T2-weighted sequence where liver values
were related to the signal from skeletal muscle, a linear
relationship of biopsy LIC to MRI SIR was shown up to
approximately 29 mg/g dw. In the R2* method published
by Wood, [17] LIC derived from R2* values are broadly
similar to T2*-LIC values obtained in our paper: an R2* of
300 s−1 predicted a mean LIC of 8 mg/g dw with 95%
prediction bands from approximately 3 to 12 mg/g dw,
while for 600 s−1 15 (9–20)mg/g dw, respectively [17].0 250 500 750 1
0
10
20
30
40
50
60
R2
LI
C
 [m
g/
g 
dw
]
Wood
Anderson
RBH-UCLH
Hankins
Figure 4 Slope comparison of R2* LIC calibration models. Slope comp
by L. Anderson LIC = 0.0146(R2*)-0.27 (green), by J. Wood LIC = 0.0254(R2*)
method (RBH-UCLH) LIC = 0.032(R2*)-0.14 (red).Hankins [18] examined LIC <30 mg/g dw and from
their Figure 1A it can be observed that, similarly to
Wood et al., 300 s−1 relates to mean LIC of 8 mg/g
dw, with prediction bands between 4.5-12, while for
600 s−1 – to 16.5 (12.5-20) mg/g dw.
Our data show higher LIC values for similar R2* than
those quoted in the above two papers (Figure 4) and the
reason for this is at least twofold. Treatment of biopsy
specimens differed, with our samples washed in xylene
before embedding in paraffin, which dissolves lipids,
reduces dry weight and increases iron-to-weight ratio
more than when fresh samples are dried before iron
quantification [38] as in Wood and Hankins studies.
Furthermore, the offset model used by Wood for R2*
measurement [17] is different from our truncation
model used in this study, whereas truncation model used
by Hankins is really an offset model with direct noise
floor subtraction based on Anderson’s early model. We
have demonstrated [39] that, compared with the truncation
model, the offset model tends to overestimate R2* due to
its technique for noise compensation. For this particular
reason, if R2* is measured using our truncation model,
lower LIC values are expected than if calculated by using
the calibration equations from Wood or Hankins.
This finding also highlights the importance of using a
calibration equation appropriate to the analysis technique
to get an accurate LIC estimation in clinical practice.
Conclusions
In conclusion, the R2* method described in this paper
shows near-linearity to biopsy LIC values over a wide clin-
ical range. There is good inter-observer reproducibility,000 1250 1500 1750 2000
* [s-1]
arison of R2* based LIC calibration methods (after J. Hankins et al. [18]):
+ 0.202 (orange), by J. Hankins LIC = 0.028(R2*)-0.45 (blue), our
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http://jcmr-online.com/content/16/1/40however it is not possible to know to what extent the
decrease in reproducibility at high LIC values is a
consequence of the inhomogeneity in liver iron obtained
by biopsy and to what extent this is a reflection of the T2*
measurements, but this phenomenon has also been noted
with the R2 Ferriscan technique and SQUID. Differences
from other R2*/T2* derived LIC calibrations may be ex-
plained by differences in post-biopsy sample processing
and fitting algorithms. Poor agreement between T2*LIC
and R2LIC, even at low magnitude is not derived
from ROI- and reproducibility-related variability of both
methods but likely stems from different sensitivity of R2
and R2* to iron distribution and noise sources.
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